Advances in treatment of pulmonary arterial hypertension: patent review

References

• Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(SupplD):42–50
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104–109.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–41.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Stacher E, Robinson J, et al. Pathology of pulmonary hypertension. Clin Chest Med. 2013;34:639–650.
   PubMed Web of Science ®Google Scholar
• Rai PR, Cool CD, King JA, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:558–564.
   PubMed Web of Science ®Google Scholar
• Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res. 2014;115:148–164.
   PubMed Web of Science ®Google Scholar
• Palmer MJ. Leads for the treatment of pulmonary hypertension. Expert Opin Ther Pat. 2009;19:575–592.
   PubMed Web of Science ®Google Scholar
• Vaidya B, Gupta V. Novel therapeutic approaches for pulmonary arterial hypertension: unique molecular targets to site-specific drug delivery. J Control Release. 2015;211:118–133.
   PubMed Web of Science ®Google Scholar
• Vaillancourt M, Ruffenach G, Meloche J, et al. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can J Cardiol. 2015;31:407–415.
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Ghofrani HA, Wilkins MR, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8:443–455.
   PubMed Web of Science ®Google Scholar
• Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172:105–113.
   PubMed Web of Science ®Google Scholar
• Nogueira-Ferreira R, Ferreira R, Henriques-Coelho T. Cellular interplay in pulmonary arterial hypertension: implications for new therapies. Biochim Biophys Acta. 2014;1843:885–893.
   PubMed Web of Science ®Google Scholar
• Newman JH, Phillips JA 3rd, Loyd JE. Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann Intern Med. 2008;148:278–283.
   PubMed Web of Science ®Google Scholar
• Paulin R, Meloche J, Bonnet S. STAT3 signaling in pulmonary arterial hypertension. Jakstat. 2012;1:223–233.
   PubMedGoogle Scholar
• Farkas D, Alhussaini AA, Kraskauskas D, et al. Nuclear factor kappaB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats. Am J Respir Cell Mol Biol. 2014;51:413–425.
   PubMed Web of Science ®Google Scholar
• Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Respir Rev. 2013;22:217–226.
   PubMedGoogle Scholar
• Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:62S–7S.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:68S–72S.
   PubMed Web of Science ®Google Scholar
• Makowski CT, Rissmiller RW, Bullington WM. Riociguat: a novel new drug for treatment of pulmonary hypertension. Pharmacotherapy. 2015;35:502–519.
   PubMed Web of Science ®Google Scholar
• Bell AS, Palmer MJ. Novel phosphodiesterae type 5 modulators: a patent survey (2008-2010). Expert Opin Ther Pat. 2011;21:1631–1641.
   PubMed Web of Science ®Google Scholar
• Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183:1723–1729.
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med. 2003;2:123–137.
   PubMedGoogle Scholar
• Hirshberg A, Thomson SR, Bade PG, et al. Pitfalls in the management of penetrating chest trauma. Am J Surg. 1989;157:372–375. discussion 6.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. Primary Pulmonary Hypertension Study G. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533.
   PubMed Web of Science ®Google Scholar
• Lajoie AC, Lauziere G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4:291–305.
   PubMed Web of Science ®Google Scholar
• Bourge RC, Waxman AB, Gomberg-Maitland M, et al. Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the DellVery of PAH trial. Chest. 2016;150:27–34.
   PubMed Web of Science ®Google Scholar
• Hu J, Xu Q, McTiernan C, et al. Novel targets of drug treatment for pulmonary hypertension. Am J Cardiovasc Drugs. 2015;15:225–234.
   PubMed Web of Science ®Google Scholar
• Aguiar R, Araujo C, Martins-Coelho G, et al. Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years. Arthritis Care Res (Hoboken). 2017;69:257–262.
   PubMed Web of Science ®Google Scholar
• Spiekerkoetter E, Tian X, Cai J, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest. 2013;123:3600–3613.
   PubMed Web of Science ®Google Scholar
• Spiekerkoetter E, Sung YK, Sudheendra D, et al. Low-dose FK506 (tacrolimus) in end-stage pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192:254–257.
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115:165–175.
   PubMed Web of Science ®Google Scholar
• Frost AE, Barst RJ, Hoeper MM, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant. 2015;34:1366–1375.
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Bonnet S, Wu X, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95:830–840.
   PubMed Web of Science ®Google Scholar
• Monteiro P, Duarte AI, Goncalves LM, et al. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia. Eur J Pharmacol. 2004;503:123–128.
   PubMed Web of Science ®Google Scholar
• Meloche J, Paulin R, Provencher S, et al. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Curr Vasc Pharmacol. 2015;13:331–340.
   PubMed Web of Science ®Google Scholar
• Courboulin A, Paulin R, Giguere NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208:535–548.
   PubMed Web of Science ®Google Scholar
• Ruffenach G, Chabot S, Tanguay VF, et al. Role for runt-related transcription factor 2 in proliferative and calcified vascular lesions in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2016;194:1273–1285.
   PubMed Web of Science ®Google Scholar
• Sharma S, Umar S, Potus F, et al. Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation. 2014;130:776–785.
   PubMed Web of Science ®Google Scholar
• Ban HS, Uto Y, Won M, et al. Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015). Expert Opin Ther Pat. 2016;26:309–322.
   PubMed Web of Science ®Google Scholar
• Paulin R, Meloche J, Jacob MH, et al. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2011;301:H1798–809.
   PubMed Web of Science ®Google Scholar
• Kim J. Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension. Mol Cells. 2014;37:196–201.
   PubMed Web of Science ®Google Scholar
• Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013;19:74–82.
   PubMed Web of Science ®Google Scholar
• Chandra SM, Razavi H, Kim J, et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2011;31:814–820.
   PubMed Web of Science ®Google Scholar
• Brash L, Barnes G, Brewis M, et al. Apelin improves cardiac output in patients with pulmonary arterial hypertension. Eur Res J. 2015;46:PA2107.
   Google Scholar
• Andersen CU, Hilberg O, Mellemkjaer S, et al. Apelin and pulmonary hypertension. Pulm Circ. 2011;1:334–346.
   PubMedGoogle Scholar
• Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof. WO2015061720A2 (2015)
   Google Scholar
• Concert Pharmaceuticals, Inc. Endothelin receptor antagonists. US8080549 B2 (2011).
   Google Scholar
• Bayer Intellectual Property Gmbh Substituted fused imidazoles and pyrazoles and use thereof. US 9023849B2 (2015).
   Google Scholar
• Bayer Healthcare Ag Carbamate-substituted pyrazolopyridines. WO 2003095451A1 (2003).
   Google Scholar
• Bayer Intellectual Property Gmbh Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators. US 20140228366 A1 (2014).
   Google Scholar
• Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators. US 8569339B2 (2013).
   Google Scholar
• Ironwood Pharmaceuticals, Inc. 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators. WO2013101830A1 (2013).
   Google Scholar
• Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension. WO2007050783A2 (2007).
   Google Scholar
• Theravance, Inc. Serotonin reuptake inhibitors. WO2012051103A1 (2012).
   Google Scholar
• Janssen Pharmaceutica Nv 5-ht2b receptor antagonists. WO2012028614A1 (2012).
   Google Scholar
• Alkhatib Y, Albashaireh D, Al-Aqtash T, et al. The role of tyrosine kinase inhibitor “Lapatinib” in pulmonary hypertension. Pulm Pharmacol Ther. 2016;37:81–84.
   PubMed Web of Science ®Google Scholar
• Godinas L, Guignabert C, Seferian A, et al. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med. 2013;34:714–724.
   PubMed Web of Science ®Google Scholar
• Jasinska-Stroschein M, Owczarek J, Plichta P, et al. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension. Pharmacology. 2014;93:145–150.
   PubMed Web of Science ®Google Scholar
• Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation. 2008;118:2081–2090.
   PubMed Web of Science ®Google Scholar
• Pitsiou G, Zarogoulidis P, Petridis D, et al. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment. Drug Des Devel Ther. 2014;8:1753–1763.
   PubMed Web of Science ®Google Scholar
• Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds. US8354408B2 (2013).
   Google Scholar
• Cytopia Research Pty Ltd Phenyl amino pyrimidine compounds and uses thereof. WO2008109943A1 (2008).
   Google Scholar
• Novartis Ag Salts of an ip receptor agonist. WO 2013105066 A1 (2013).
   Google Scholar
• Novartis Ag Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders. WO 2013105057 A1 (2013).
   Google Scholar
• Novartis Ag, Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension. WO 2013030802 A1 (2013).
   Google Scholar
• Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds. US 8354408 B2 (2013).
   Google Scholar
• Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest. 2005;115:2691–2694.
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811–2821.
   PubMed Web of Science ®Google Scholar
• Irm LLC Compounds and compositions as c-kit kinase inhibitors. WO2013033167A1 (2013).
   Google Scholar
• O’Callaghan DS, Savale L, Montani D, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol. 2011;8:526–538.
   PubMed Web of Science ®Google Scholar
• Duong-Quy S, Bei Y, Liu Z, et al. Role of Rho-kinase and its inhibitors in pulmonary hypertension. Pharmacol Ther. 2013;137:352–364.
   PubMed Web of Science ®Google Scholar
• Guilluy C, Eddahibi S, Agard C, et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med. 2009;179:1151–1158.
   PubMed Web of Science ®Google Scholar
• Liu AJ, Ling F, Wang D, et al. Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip(1) via the ERK signal pathway. Chin Med J (Engl). 2011;124:3098–3104.
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Yamada N, Matsubara H, et al. Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013;77:2619–2625.
   PubMed Web of Science ®Google Scholar
• Pankey EA, Byun RJ, Smith WB 2nd, et al. The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat. Can J Physiol Pharmacol. 2012;90:825–835.
   PubMed Web of Science ®Google Scholar
• Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use. WO2011075415A1 (2011).
   Google Scholar